Last reviewed · How we verify
mupirocin and chlorhexidine
At a glance
| Generic name | mupirocin and chlorhexidine |
|---|---|
| Also known as | bactroban, chlorhexidine gluconate, Bactroban® Nasal Ointment, Lifo-Scrub® |
| Sponsor | loren g miller |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Effect of S. Aureus Skin Decolonization on Disease Severity in Atopic Dermatitis Patients (PHASE4)
- Staph Household Intervention for Eradication (SHINE) (PHASE4)
- STaph Aureus Resistance-Treat Early and Repeat (STAR-TER) (PHASE2)
- Bacterial Decolonization Plus Intraoperative Angiography for Soft Tissue Sarcomas Receiving Preoperative Radiotherapy (CONCERTO) (PHASE2)
- Effectiveness of Screening and Decolonization of S. Aureus to Prevent S. Aureus Surgical Site Infections in Surgery Outpatients
- Staph Intervention for Effective Local Defense (PHASE4)
- Bacterial Decolonization Within Dyads (NA)
- The Effect of Bacterial Decolonization Before Skin Cancer Surgery on Infection Rate of Lower Extremity Wounds Left Open to Heal (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- mupirocin and chlorhexidine CI brief — competitive landscape report
- mupirocin and chlorhexidine updates RSS · CI watch RSS
- loren g miller portfolio CI